

Expression Pathology

FOR IMMEDIATE RELEASE

Expression Pathology Appoints New President and CEO

Rockville, MD: February 1, 2012: **Expression Pathology Inc. announced today that Dr. Jon Burrows has been appointed President and Chief Executive Officer.** Dr. Burrows has served as Expression Pathology's Head of R&D and Executive Vice President since 2009. He has been instrumental in the development of the company's technology platform and strategic direction. He replaces Mr. Casey Eitner, who will remain on the board of directors.

Dr. Burrows brings extensive experience in development of clinical tissue assays and a deep understanding of cancer pathways and drug development. Prior to joining Expression Pathology he held management roles at Ventana Medical Systems (a member of the Roche group) in business development and R&D with responsibilities for managing companion diagnostic development collaborations with major biopharmaceutical companies. Previous roles included research and management positions with Novartis, Chiron, Rigel and Sugen/Pharmacia.

About Expression Pathology

Expression Pathology is advancing personalized medicine assays that measure tumor signaling networks—at the functional protein level—in routine formalin-fixed paraffin-embedded (FFPE) patient tissue to individualize and improve cancer treatment decisions. The company is developing proprietary Liquid Tissue®-SRM companion diagnostic tests to support the development of drugs in clinical trials and to improve patient selection for targeted therapies already on the market. The company's rapidly expanding menu of assays includes many of the key protein pathways for which targeted therapies are being developed, including EGFR, IGF-1R, SPARC, SRC, HER2, HER3, and cMET.

For more information, please contact

Peter Tunon
Vice President, Sales and Marketing
Expression Pathology Inc.
9620 Medical Center Drive
Rockville, MD 20850

Phone: 301.977.3654

Email: p.tunon@expressionpathology.com